B lymphocytes in neuromyelitis optica - Wikidata - awgldk - TriplyDB

B lymphocytes in neuromyelitis optica

B lymphocytes in neuromyelitis optica

http://www.wikidata.org/entity/Q35591039

about

B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies Role of regulatory b cells in neuroimmunologic disorders Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.Microarray Analysis of lncRNA and mRNA Expression Profiles in Patients with Neuromyelitis Optica.The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.The chronically inflamed central nervous system provides niches for long-lived plasma cells.GRP78 autoantibodies initiate the breakdown of the blood-brain barrier in neuromyelitis optica.Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders.Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders.Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.[Optical coherence tomography in neuromyelitis optica spectrum disorders].Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis Objective assessment of a relative afferent pupillary defect by B-mode ultrasound

P2860

Q26770852-33833AE8-C4A5-4988-BCCE-D70A47B0FDF8 Q28067334-827B3F06-EDE7-43E9-95E8-4D9DA3D3B2DA Q28077219-AF25880C-96FB-4775-BF3B-2E5350EAD670 Q37645937-B1CE65AD-9EE7-42F2-904F-D07C7A4F17D4 Q37707340-926B97A0-3BA3-45BC-9203-8CCF115098BD Q38714054-6C894427-763C-41F8-8F93-A48059CF6DB3 Q40281523-4D5EE5B7-A49D-4532-99F2-2A70C3EDB7DE Q41962690-B5FB0988-59B5-4D68-9ADF-2D1F186638C1 Q42361527-ACF18A38-5D51-4267-8F60-2C776E2B7D09 Q47116115-1F901FED-2D66-4CC4-9534-85025BF449E0 Q47145475-AB2F56E7-AB9C-4978-9B0E-24B6B0A0387B Q47192132-31B8A2B2-8B0B-4AE0-9B2D-285773ADEF70 Q47827665-62A6FAD7-BB88-484E-AA97-D2A119732420 Q48172406-ED29540F-52BC-4A06-8E0C-4A09E8F03CD8 Q48302225-2EBEA0D1-5EFB-4059-A369-C14B55B71EEF Q49978385-79C714E3-9E3D-4CE7-B74B-0DA59535BEA5 Q50101454-B310A48E-8E29-4684-B0BB-3836FC9D2D08 Q52668258-1346850D-9F38-4F41-94F5-6E5809ECB69C Q55283747-65E24398-FCC3-4C3C-AA06-5AF1168DC42A Q58573155-973771A6-E53E-4F7D-8A94-15E4ED731B27 Q58701679-43B700EB-16BA-4DA2-893C-C43649F30EFF

P2860

B lymphocytes in neuromyelitis optica

http://www.wikidata.org/entity/Q35591039

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

B lymphocytes in neuromyelitis optica

@ast

B lymphocytes in neuromyelitis optica

@en

type

label

B lymphocytes in neuromyelitis optica

@ast

B lymphocytes in neuromyelitis optica

@en

prefLabel

B lymphocytes in neuromyelitis optica

@ast

B lymphocytes in neuromyelitis optica

@en

P1433

Q35591039-C7924C2B-5E8E-47FC-8188-E202FAE6C6B9

P1476

Q35591039-1453507A-3076-414B-B466-AD0C25F08EBC

P2093

Q35591039-046E1660-6927-42AC-A496-76ABC072E6D0

Q35591039-1C6A2BCC-D70E-48B9-A308-1278F9C5FF7C

Q35591039-227B1630-2FA3-45E0-AA91-97BBB1DD9E6D

Q35591039-3B07D55B-981D-40DB-A954-74187377D248

Q35591039-53E4C289-FB9E-4933-A0EB-28885E0881B4

Q35591039-6902A479-444E-4466-8F92-4167BFB65A90

Q35591039-869E0516-ACAE-45C7-BEC6-7332AF8C43E1

Q35591039-932C497B-A7D0-42A0-B5AA-0EF8935C8B15

Q35591039-E565438F-0EBC-466E-8456-F65BC6204E53

Q35591039-ECD08738-A881-48B6-B1A9-4FE4E1631A7C

P2860

Q35591039-081601F7-BB2C-4895-B18F-7F3F3101393B

Q35591039-0F028821-8B47-41B7-855F-6E5D7A327ADD

Q35591039-12712E79-53BD-4DF0-BAF5-873B6FBDE89D

Q35591039-1613C1AD-3DFA-497D-B2FB-C68758802FDC

Q35591039-1C62AA1B-2804-4789-B848-8F182B04A4D8

Q35591039-2210DCA6-1857-4E49-8E6E-08EF612DADCF

Q35591039-23A088CC-8E0D-4244-BEF1-D6EBEF4FBEBD

Q35591039-279C8BFC-194A-446B-8B5C-BC8EAE8A83D2

Q35591039-298F6628-202B-4218-ABDE-E93662153F19

Q35591039-2CB3C856-2D3D-4273-9E3A-849FD0D1F2E6

P304

Q35591039-1F8518A3-3E47-4F71-8E3E-3C16128079DF

P31

Q35591039-BA746DA0-2F2C-43D4-95E8-C04331351A1F

P356

Q35591039-266A4054-4356-4EA8-8E66-BA3583753514

P433

Q35591039-CD239D34-0750-45D7-BE46-7C5BB11BDF3A

P478

Q35591039-90971A89-D9C0-4915-BE8A-4EA401C930FC

P577

Q35591039-64ADB084-014F-476A-ADEB-938B395C841B

P5875

Q35591039-9A7F4A2A-9469-4247-A54A-424E2A0CB7D9

P698

Q35591039-1FAE6534-0FD4-4B6B-ACD5-FD043205169B

P932

Q35591039-7EE2DD87-92FD-4716-AF86-D3BA97EB2F42

P356

NXI.0000000000000104

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

B lymphocytes in neuromyelitis optica

@en

P2093

Amit Bar-Or

http://www.w3.org/2001/XMLSchema#string

Bernhard Hemmer

http://www.w3.org/2001/XMLSchema#string

Christine Stadelmann

http://www.w3.org/2001/XMLSchema#string

H-Christian von Büdingen

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Bennett

http://www.w3.org/2001/XMLSchema#string

Kevin C O'Connor

http://www.w3.org/2001/XMLSchema#string

Michael R Yeaman

http://www.w3.org/2001/XMLSchema#string

Olaf Stuve

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Terry J Smith

http://www.w3.org/2001/XMLSchema#string

P2860

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

B-cell tolerance checkpoints in health and autoimmunity

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Predominant autoantibody production by early human B cell precursors

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

The spectrum of neuromyelitis optica.

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Interleukin-35 induces regulatory B cells that suppress autoimmune disease.

Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance.

P304

e104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000104

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276353718

http://www.w3.org/2001/XMLSchema#string

P698

25977932

http://www.w3.org/2001/XMLSchema#string

P932

4426682

http://www.w3.org/2001/XMLSchema#string